Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Public ClinicalTrials.gov record NCT07416188. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/Phase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Study identification
- NCT ID
- NCT07416188
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Enrollment
- 40 participants
Conditions and interventions
Conditions
- Brain Cancer
- Brain and Central Nervous System Tumors
- GBM
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- Glioblastoma Multiforme
- Glioblastomas
- Glioma
- Glioma, Malignant
- Grade IV Astrocytoma
- High Grade Glioma
- Recurrent Glioblastoma
- Recurrent Glioma (Glioblastoma Multiforme)
- Recurrent Tumor
- Recurring Glioblastoma
- Relapsed Cancer
Interventions
- Conventional Surgery or Biopsy Procedure
- LMP744 Drug
Procedure · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 5, 2026
- Primary completion
- Dec 30, 2030
- Completion
- Dec 30, 2032
- Last update posted
- Apr 30, 2026
2026 – 2032
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07416188, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 30, 2026 · Synced May 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07416188 live on ClinicalTrials.gov.